UMIN-CTR Clinical Trial

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000021277
Receipt No. R000024541
Scientific Title Surgical reconstruction using the hyper dry human amniotic membrane : recurrence pterygium (proliferative tissue is limited to a thing more than the limbus.)
Date of disclosure of the study information 2016/03/01
Last modified on 2020/07/15 (Ver. 8)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Surgical reconstruction using the hyper dry human amniotic membrane : recurrence pterygium (proliferative tissue is limited to a thing more than the limbus.)
Acronym Surgical reconstruction using the hyper dry human amniotic membrane
Scientific Title Surgical reconstruction using the hyper dry human amniotic membrane : recurrence pterygium (proliferative tissue is limited to a thing more than the limbus.)
Scientific Title:Acronym Surgical reconstruction using the hyper dry human amniotic membrane
Region
Japan

Condition
Condition recurrence pterygium
Classification by specialty
Ophthalmology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Confirm non-recessive efficacy and safety
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase I,II

Assessment
Primary outcomes It is the presence or absence of recurrence until 52 weeks after a surgical operation
Key secondary outcomes (1) Decimal visual acuity tests
(2) Ophthalmotonometry
(3) An examination for slit lamp microscopy and anterior segment of eyeball OCT
(4) Tensile speed of the pterygium tissue (measure it by anterior segment of eyeball OTC, and calculate it)
(5) Funduscopy
(6) A growth rate of the tissue

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Device,equipment
Interventions/Control_1 (1) After Benoxil ophthalmic solution dropping lotion in the eyes anesthesia, perform washing eyes, disinfection.
(2) After draping, put on ecarteur.
(3) Add Xylocaine anesthesia to pterygium body by subconjunctival injection under a microscope(We use general anesthesia for the hope of patients).
(4) Tear off corneal epithelium close against a front of the pterygium head.
(5) Ablate pterygium tissue using a golf sword to the limbus from the head.
(6) Ablate episcleral conjunctival epithelium and Tenon pouch enough and denude a sclera and excise pterygium.
(7) Douche it in a raw diet of approximately 300 ml after insertion attachment under 3-5min conjunctiva with the microsponge which we soaked with 0.04% MMC enough.
(8) The MMC becomes out of an accommodation to use it for a purpose to inhibit an activation (recurrence of the re-pterygium) of the subconjunctival proliferative tissue
(9) Match the stromal aspect of the hyper dry human desiccation cowl (HD cowl) with a sclerotic exposed surface and trim the part of the resection side with ophthalmology cusp sword.
(10) After put an HD cowl on the wounded surface, and arrival at sewing did an HD cowl to a sclera, repeat a conjunctiva stump on the top, and sew it up in a 1mm interior position; do.
(11) Have top and bottom right and left move an eyeball and check follows and add suturation, if necessary( We confirm after consciousness returned in the case of a general anesthesia).
(1) Is eye movement smooth?
(2) Is there not the pull companion whom it is impossible for conjunctiva to do?
(3) Does a suture not come off?
(12) Steroid subconjunctival injection or eye drops etc. is provided because of resolution and picks up a contact lens for treatment when corneal epithelium of the pupillary area greatly suffers a loss.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) age: The patients who relatively have good Patient 2) overall status of (at the agreement acquisition) 20 years old or older
3) The patients whom pathologic proliferative tissue invaded in recurrent pterygium across limbus.
4) The patients whom it is judged to be available for observation, the testing that conformed to a study enforcement plan and a survey
Key exclusion criteria 1) onset pterygium patient or pseudopterygium patients.
2)The patients whom a doctor judged safely for 2) study period if it was difficult hospital visiting and to come home.
3)The patients who complicate eye infection with 3) activity.
4)The patients who plan the enforcement of eye operations for evaluation eyes effective during 4) study period in (we assume the agreement acquisition study initiation).
5)one eyes are the patients of enucleation eyes or evisceration eyes.
6)For the group medicine of the planned drug (dropping lotion in the eyes anesthetic agent, fluorescein) to use during 6) study period, it is the patients with a history of the drug allergy.
7)The patients (saying that, however, the subjects who do not receive the study drug are possible) who participated in other studies or clinical studies within six months.
8)The patients whom a doctor judged as an object of this study in testing at pregnancy or 9 childbearing patients) agreement acquisition that we might be pregnant or hoped for pregnancy during study period or did not use appropriate contraception for if inadequate.
Target sample size 40

Research contact person
Name of lead principal investigator
1st name Atsushi
Middle name
Last name Hayashi
Organization University of Toyama
Division name Department of Ophthalmology
Zip code 9300194
Address Sugitani 2630, Toyama City, Toyama Prefecture
TEL 076-434-7363
Email ahayashi@med.u-toyama.ac.jp

Public contact
Name of contact person
1st name Atsushi
Middle name
Last name Hayashi
Organization University of Toyama
Division name Department of Ophthalmology
Zip code 9300194
Address Sugitani 2630, Toyama City, Toyama Prefecture
TEL +81-76-434-7363
Homepage URL
Email ahayashi@med.u-toyama.ac.jp

Sponsor
Institute Toyama University Hospital
Institute
Department

Funding Source
Organization Toyama University Hospital
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor Takaoka city hospital, Nagasaki University Hospital, Toho University Omori Medical Center, Matsue Red Cross Hospital, Kochi Medical School Hospital, University of Occupational and Environmental Health, Yamagata University Hospital, Akita University Hospital, University of Fukui Hospital, The University of Tokyo Hospital, Oita University Hospital, Hiroshima University Hospital, Shimane University Hospital
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethics Committee, University of Toyama
Address Sugitani 2630, Toyama City, Toyama Prefecture
Tel 076-434-2281
Email rinri@adm.u-toyama.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 富山大学附属病院(富山県)、長崎大学病院(長崎県)、東邦大学医療センター大森病院(東京都)、秋田大学医学部付属病院(秋田県)、松江赤十字病院(島根県)、高知大学医学部附属病院(高知県)、山形大学医学部附属病院(山形県)、福井大学医学部附属病院(福井県)

Other administrative information
Date of disclosure of the study information
2016 Year 03 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2015 Year 10 Month 26 Day
Date of IRB
2015 Year 10 Month 26 Day
Anticipated trial start date
2016 Year 04 Month 25 Day
Last follow-up date
2017 Year 04 Month 25 Day
Date of closure to data entry
2022 Year 03 Month 31 Day
Date trial data considered complete
2022 Year 04 Month 30 Day
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 03 Month 01 Day
Last modified on
2020 Year 07 Month 15 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024541